tirzepatide 2024 yields sustained weight reduction in obesity and prediabetes, finds study FDA Approves Tirzepatide (Zepbound) as

While medical professionals raise concerns around injectable applications due to infection risk, topical formats, lip treatments, and hybrid primers present significant whitespace for expansion

Research shows that this weight loss isnt sustainable for most following cessation of the drug

Common ones are: Abdominal pain Dizziness Sweating Confusion Headache Shakiness Fast heartbeat Mood changes Nausea Diarrhea Vomiting Decreased appetite Constipation Indigestion Allergic reactions at the injection site and hair loss are also reported for Zepbound, but not Mounjaro

SU=sulfonylurea

What is the future of GLP-1 receptor agonists